Establishment e- xmatch FDA Approval/ Status

Status of FDA permission requirements for Blood Bank establishment use of electronic crossmatch as of November 18, 1999:

Because 21 CFR 606.151 requires a serologic crossmatch those hospitals (all
hospitals) who wish to use the electronic crossmatch must apply for a
variance to 21 CFR 606.151 (as allowed by 21 CFR 640.120) to gain written
permission from FDA prior to implementation. At this time, we review their
validation prior to approving the variance. Since everyone is legally
required to follow the CFR, this rule applies to everyone. To use the
electronic crossmatch without written FDA approval of the variance is
breaking the law.

But, things are changing. There is a change in 21 CFR 606.151 in process
now which would redefine the “crossmatch” in a way that the request for a
variance would no longer be necessary; however, it is unclear when this
change will be effective. When, and if the change is finalized, the
on-site validation would be performed and the records kept on site. Those
validation records would be examined by the FDA investigator during the next
routine inspection. Transfusion services which are not inspected by the FDA
should have those validation records inspected during the next HCFA
inspection [by a Memorandum of Understanding with HCFA, they are supposed to
inspect against CFR rules on behalf of FDA].

SoftwareCPR Training Courses:

IEC 62304 and other emerging standards for Medical Device and HealthIT Software

Our flagship course for preparing regulatory, quality, engineering, operations, and others for the activities and documentation expected for IEC 62304 conformance and for FDA expectations. The goal is to educate on the intent and purpose so that the participants are able to make informed decisions in the future.  Focus is not simply what the standard says, but what is meant and discuss examples and approaches one might implement to comply.  Special deep discount pricing available to FDA attendees and other regulators.

3-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Brian Pate

Next public offering:  June 24-26, 2025 (Boston, MA)

Multiple participants from the same company: If you register 5 or more from the same company before March 15, 2025, receive a special discounted registration of $1999 per person.  These registrations may be transferred to another person at any time. Email training@softwarecpr.com to register and secure the TEAM discount.

 

For private, in-house courses, please contact us.

Email training@softwarecpr.com for more info.

 


 

Being Agile & Yet Compliant (Public)

Our SoftwareCPR unique approach to incorporating agile and lean engineering to your medical device software process training course is now open for registration!

  • Agile principles that align well with medical
  • Backlog management
  • Agile risk management
  • Incremental and iterative software development lifecycle management
  •  Frequent release management
  • And more!

3 days virtual (Zoom) with group exercises, quizzes, examples, Q&A.

Lead Instructor: Mike Russell

Next public offerings:

  • Americas: 11-13 February 2025
  • EU/Eastern Europe/Middle East/Africa/Atlantic/eastern South America: 18-20 February 2025
  • Southern Central Northeastern Pacific: 24-26 February 2025
See our post titled: 1st Quarter 2025 Agile Compliant Courses Scheduled

 

Medical Device Cybersecurity (Public or Private)

This course takes a deep dive into the US FDA expectations for cybersecurity activities in the product development process with central focus on the cybersecurity risk analysis process. Overall approach will be tied to relevant standards and FDA guidance documentation. The course will follow the ISO 14971:2019 framework for overall structure but utilize IEC 62304, IEC 81001-5-1, and AAMI TIR57 for specific details regarding cybersecurity planning, risk characterization, threat modeling, and control strategies.

2-days onsite with group exercises, quizzes, examples, Q&A.

Instructor: Dr Peter Rech, 2nd instructor (optional)

Next public offering:  TBD

Corporate Office

15148 Springview St.
Tampa, FL 33624
USA
+1-781-721-2921
Partners located in the US (CA, FL, MA, MN, TX) and Canada.